title: Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
abstract: Tumour vasculature is generally disordered because of the production of excessive angiogenic factors by tumour cells, which results in tumour progression and reduces the effectiveness of radiotherapy or chemotherapy. Transient anti-angiogenic therapies that regulate tumour vascular morphology and function and improve the efficiency of antitumour therapy are under investigation. Recombinant human endostatin (Endostar/rhES) is a vascular angiogenesis-disrupting agent that has been used to treat non-small cell lung cancer (NSCLC) in the clinical setting. In this study, we used gold nanoparticles (AuNPs) as a drug-delivery system (DDS) for targeted tumour delivery of rhES for short therapy, which resulted in transient tumour vascular normalization, reduced permeability and hypoxia, strengthened blood vessel integrity, and increased blood-flow perfusion. Moreover, combination therapy with 5-FU over this timeframe was substantially more effective than 5-FU monotherapy. In conclusion, our research demonstrates the potential use of AuNPs as a drug-delivery platform for transporting rhES into a tumour to induce transient tumour vascular normalization and enhance the antitumour efficacy of cytotoxic drugs.
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Xiaoxu
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Du
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Shuhao
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Yang
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Ding
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Wende
authors.initials: W
authors.lastname: Yang
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Pan
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Histology and Embryology, Medical School of Jinan University, Guangzhou 510632, China.
authors.forename: Li
authors.initials: L
authors.lastname: Qin
authors.affiliation: Department of General Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
authors.forename: Yunlong
authors.initials: Y
authors.lastname: Pan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage*; D043169:Endostatins / Q000008:administration & dosage*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006046:Gold / Q000008:administration & dosage*; D064593:Heterografts; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage*; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004337:Drug Carriers; D043169:Endostatins; D011994:Recombinant Proteins; D006046:Gold; D005472:Fluorouracil